IRIS
CLERICO, ALDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 57.286
EU - Europa 36.269
AS - Asia 21.397
SA - Sud America 3.568
Continente sconosciuto - Info sul continente non disponibili 428
AF - Africa 409
OC - Oceania 33
Totale 119.390
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 55.771
GB - Regno Unito 14.487
SG - Singapore 7.867
RU - Federazione Russa 6.676
CN - Cina 6.087
UA - Ucraina 3.967
IT - Italia 3.923
VN - Vietnam 3.123
BR - Brasile 2.855
DE - Germania 2.433
HK - Hong Kong 1.931
CA - Canada 1.110
SE - Svezia 958
FI - Finlandia 933
FR - Francia 868
DK - Danimarca 784
PL - Polonia 641
BD - Bangladesh 542
IN - India 376
IL - Israele 272
AR - Argentina 244
MX - Messico 205
IE - Irlanda 203
EU - Europa 202
ZA - Sudafrica 154
TR - Turchia 150
IQ - Iraq 146
ID - Indonesia 141
EC - Ecuador 111
JP - Giappone 100
VE - Venezuela 94
CO - Colombia 92
PK - Pakistan 91
NL - Olanda 87
ES - Italia 69
SA - Arabia Saudita 68
CL - Cile 65
KR - Corea 64
UZ - Uzbekistan 61
MA - Marocco 56
MY - Malesia 52
PH - Filippine 45
JM - Giamaica 44
RO - Romania 39
AE - Emirati Arabi Uniti 36
PY - Paraguay 35
JO - Giordania 34
TN - Tunisia 34
KE - Kenya 33
LT - Lituania 33
UY - Uruguay 32
EG - Egitto 30
NP - Nepal 29
AT - Austria 25
DZ - Algeria 25
AU - Australia 23
TT - Trinidad e Tobago 23
ET - Etiopia 21
NI - Nicaragua 20
PE - Perù 20
CR - Costa Rica 19
HN - Honduras 19
AZ - Azerbaigian 18
SK - Slovacchia (Repubblica Slovacca) 18
IR - Iran 15
PA - Panama 15
TH - Thailandia 15
KZ - Kazakistan 14
PT - Portogallo 14
BO - Bolivia 13
OM - Oman 13
RS - Serbia 13
TW - Taiwan 13
BH - Bahrain 12
AL - Albania 11
CH - Svizzera 11
DO - Repubblica Dominicana 11
PR - Porto Rico 11
PS - Palestinian Territory 11
SV - El Salvador 11
GT - Guatemala 10
BE - Belgio 9
BY - Bielorussia 9
CZ - Repubblica Ceca 9
LB - Libano 9
BB - Barbados 8
CI - Costa d'Avorio 8
KW - Kuwait 8
NG - Nigeria 8
NZ - Nuova Zelanda 8
QA - Qatar 8
AM - Armenia 7
AO - Angola 7
BG - Bulgaria 7
HR - Croazia 7
SN - Senegal 7
BA - Bosnia-Erzegovina 6
KH - Cambogia 6
HU - Ungheria 5
KG - Kirghizistan 5
Totale 119.068
Salva come PNG Salva come JPEG
Città #
Southend 12.638
Dallas 8.336
Woodbridge 5.122
Ann Arbor 4.000
Singapore 3.513
Chandler 3.261
San Jose 3.122
Houston 3.019
Ashburn 2.550
San Mateo 2.513
Beijing 2.409
Dearborn 1.956
Jacksonville 1.931
Hong Kong 1.830
Falls Church 1.474
Moscow 1.402
Council Bluffs 1.332
Fairfield 1.187
The Dalles 1.153
Seattle 1.069
Cambridge 949
Wilmington 847
Dong Ket 828
Milan 811
Stevenage 762
Portsmouth 694
Hefei 689
Boardman 664
Warsaw 623
Lawrence 611
Los Angeles 579
Ho Chi Minh City 565
Lauterbourg 560
Brooklyn 533
Rome 482
Pisa 471
Ottawa 461
Chicago 434
Hanoi 399
Santa Clara 367
New York 324
Buffalo 301
Helsinki 297
São Paulo 296
Tel Aviv 249
Phoenix 210
Montréal 195
Dublin 189
Old Bridge 185
Salt Lake City 177
San Diego 141
Figino 119
Beauharnois 107
Mexico City 105
Redwood City 101
Rio de Janeiro 101
Montreal 99
Munich 99
Norwalk 96
Orem 93
London 89
Tampa 89
Johannesburg 86
Tokyo 86
Da Nang 85
Chennai 83
Toronto 77
Elk Grove Village 73
Stockholm 68
Haiphong 64
Denver 63
Belo Horizonte 61
Atlanta 60
Tashkent 54
Turin 53
Columbus 52
San Francisco 52
Baghdad 51
Boston 51
Brasília 51
Frankfurt am Main 51
Dhaka 50
Curitiba 49
Naples 48
Bologna 46
Porto Alegre 45
Guangzhou 44
Miami 43
Hải Dương 42
Florence 41
Amsterdam 40
Fremont 40
Kansas City 40
Augusta 39
Poplar 39
Washington 39
Istanbul 38
Seoul 38
Manchester 37
Biên Hòa 36
Totale 81.823
Salva come PNG Salva come JPEG
Nome #
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.709
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 702
[ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients] 493
siRNA-mediated targeting of endothelial VWF prevents ET-1 upregulation in porcine aortic endothelial cells chronically exposed to angiotensin II 465
Downregulation of von Willebrand Factor prevents Ang II-induced endothelin-1 expression independently of eNOS activation in porcine endothelial cells 449
Gene silencing of endothelial von Willebrand Factor attenuates angiotensin II-induced endothelin-1 expression in porcine aortic endothelial cells. 411
Cardiac biomarker testing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides 375
A chemiluminescence immunoassay for CA 15-3, CA 125, CA 19-9: evaluation using quality control sera assayed in an interlaboratory survey 348
Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform 337
State of the art of BNP and NT-proBNP immunoassays: The CardioOrmoCheck study 336
Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: some results. 336
Effect of Coronary Atherosclerosis and Myocardial Ischemia on Plasma Levels of High-Sensitivity Troponin T and NT-proBNP in Patients with Stable Angina 335
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 334
Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin i 333
Abnormal circulating levels of muscle enzymes and myoglobin in hypothyroidism: their significance and usefulness in follow-up of replacement therapy of the metabolic disorder 332
125I-Endothelin-1 binding sites in human cardiac tissue 332
Inibizione dell'asse ipofiso-gonadale dopo trattamento con un farmaco anabolizzante (Metandrostenolone, Dianabol) 324
The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: A multicenter study in Italy. 319
A new immunoradiometric assay for the measurement of N-terminal fragment of proatrial natriuretic peptide in human plasma: relationship with atrial and brain natriuretic peptides 318
A chromatographic method for the determination of uric acid turnover in man 316
N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives 310
A sensitive and accurate plasma noradrenaline assay using a modified fluorimetric method. 307
Evaluation of analytical performance and comparison of clinical results of the new generation method AccuTnI+3 for the measurement of cardiac troponin I using both patients and quality control plasma samples 307
Valutazione delle caratteristiche analitiche di un nuovo metodo di dosaggio del BNP 303
A ligand-receptor binding assay of urinary and circulating endogenous digitalis-like factors 300
Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia 297
Evaluation of analytical performance of a novel immunoenzymometric assay for cTnI. 297
A simplified method of measuring free triiodothyronine in serum by conbined equilibrium dialysis and gel Sephadex extraction 296
A chromatographic method for the determination of uric acid turnover in man 294
Evaluation of the analytical performance of the advanced method for cardiac troponin I for the AxSYM platform: comparison with the old method and the Access system. 293
Acute effects of intravenous amiodarone administration on thyroid function in arrhthmic patients 293
Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review 288
Cardiac biomarker testing in the clinical laboratory:Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. 288
Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: New challenges and perspectives 287
Direct comparison of B-Type Natriuretic Peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data 280
Evaluation of analytical performance and qualità specifications of a novel immunoenzymometric assay for cTnI: comparison with cTnI and cTnT immunoassays 280
A false positive case of cardiac troponin I: Which diagnostic approach? 279
Usefulness of High-Sensitive Troponin Elevation After Effort Stress to Unveil Vulnerable Myocardium in Patients With Heart Failure 279
Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia 277
A new chemiluminescence immunoassay for CA 15-3, CA 125, CA 19-9: evaluation using QC sera assayed in an interlaboratory survey 273
Acute effects of intravenous amiodarone administration on thyroid function in arrhthmic patients 273
Evaluation of reference change values for a hs-cTnI immunoassay using both plasma samples of healthy subjects and patients and quality control samples 273
Marcatori di rimodellamento e fibrosi cardiaca 272
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 271
A simple, sensitive and rapid radioimmunoassay for measurement of urinary albumin 271
Comparison of Brain Natriuretic Peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure 270
Acute effects of intravenous amiodarone on sulphate metabolites of thyroid hormones in arrhythmic patients 270
Acute effects of intravenous amiodarone on sulphate metabolite of thyroid hormones in arrhythmic patients 269
A rapid procedure for the quantization of natriuretic peptide RNAs by competitive RT-PCR in congenital heart defects 266
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 265
Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones 264
B-type natriuretic peptide secretion following scuba diving 263
ANMCO/ELAS/SIBioC Consensus Document: Biomarkers in heart failure 262
Valutazione esterna di qualità dei peptidi natriuretici BNP e NT-proBNP: risultati del programma Cardioormocheck 261
N-terminal proB-type natriuretic peptide (NT-proBNP) is superior to BNP for the detection of eraly/mild forms of heart failure 259
Forme molecolari della gamma-glutammiltransferasi: caratteristiche e biogenesis. 259
Stato dell’arte dell’immunodosaggio dei peptidi natriuretici di tipo B 259
Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance 255
Evaluation of analytical performance of immunoassay methods for cTnI and cTnT: From theory to practice 255
Hypovitaminosis D in patients with heart failure: effects on functional capacity and patients' survival 254
Criteri per la valutazione delle caratteristiche analitiche e della utilità clinica dei nuovi biomarcatori cardiaci 253
Methodological assessment of mitochondrial respiratory chain-enzyme activities in cardiac tissue 252
Natriuretic peptides (NPs): Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. 250
The 99th percentile of reference population for cTnI and cTnT assay: Methodology, pathophysiology and clinical implications 250
The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex 248
Distribution of plasma cardiac troponin-I values in healthy subjects: pathophysiological considerations 248
N-terminal fragment of brain natriuretic peptide predicts vascular health and subclinical atherosclerosis: results from MEHLP study 247
Influence of gender on circulating cardiac natriuretic hormones in patients with heart failure. 246
Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences 246
Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay of the N-terminal fragment of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. 245
Natriuretic peptide testing in primary care patients. 245
Evaluation of analytical performances using standardized analytical protocols and comparison of clinical results of the new ADVIA BNP and NT-proBNP immunoassays for the Centaur XPT platform 245
The combined use of neutrophil gelatinase-associated lipocalin and brain natriuretic peptide improves risk stratification in pediatric cardiac surgery 243
Rilevanza clinica e interpretazione dei marcatori biochimici nello scompenso cardiaco 243
Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review 241
State of the art of aldosterone immunoassays. A multicenter collaborative study on the behalf of the Cardiovascular Biomarkers Study Group of the Italian Section of European Society of Ligand Assay (ELAS) and Società Italiana di Biochimica Clinica (SIBIOC). 239
Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin i 239
Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method 239
Evaluation and Comparison with Other High-Sensitivity Methods of Analytical Performance and Measured Values of a New Laboratory Test for Cardiac Troponin I Assay 238
No variation in Hsp70 mRNA level during cardiac surgery in pediatric patients evaluated by semiquantitative RT-PCR 238
Prognostic value of combined use of B-ype natriuretic peptides and interleukine-6 in predicting cardiac mortalità in end-stage renal disease patients 238
S-nitrosoglutathione as a substrate of gamma-glutamyltransferase (GGT)- A kinetic study 238
Proposta per l’utilizzo in Pronto Soccorso delle troponine cardiache misurate con metodi di ultima generazione in pazienti con sospetto di sindrome coronarica acuta senza sopraslivellamento del tratto ST 236
C-type natriuretic peptide expression in patients with chronic heart failure: effects of aerobic training. 234
New biomarkers for risk stratifications in patients with heart failure: high-sensitivity troponin I and galectin-3 233
Cardiac troponins as biomarkers for cardiac disease 233
BNP values in the first days of life measured with an automated immunoassay platform 232
Prognostic complexity of heart failure and network analysis: the holistic risk stratification 232
Cheyne-Stokes respiration is associated with neurohormonal activation in patients with heart failure 232
Plasma gamma-glutamyltransferase fractions: diagnostic and prognostic predictive value 232
Comparison of two BNP immunoassays using the same antibodies and standard materials 231
Diagnosis of preclinical /mild heart failure with B-type natriuretic peptides: compariosn betwwen BNP and NT-proBNP immunoassay methods 230
Genomic medicine and thrombotic risk: who, when, how and why? 230
Detection of mtDNA with 4977 bp deletion in blood cells and atherosclerotic lesions of patients with coronary artery disease. 230
New and emerging biomarkers of heart failure 228
Deoxyribonucleic acid damage in human lymphocytes after percutaneous transluminal coronary angioplasty 228
Gamma-glumamyl-transferase levels are associated with inflammatory activation, myocardial dysfunction and mortality in pateints with ST-elevation myocardial infarction 226
Comparison of the diagnostic accuracy of BNP and NT-proBNP in acute and chronic heart failure. Reply Letter 225
Risk factors and prognostic value of daytime Cheyne-Stokes respiration in chronic heart failure patients 223
B-type plasma natriuretic hormone level in operated Fallot patients 223
Totale 29.532
Salva come PNG Salva come JPEG
Categoria #
all - tutte 584.651
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 584.651
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226.080 0 0 208 966 62 55 887 1.779 511 924 56 632
2022/20236.603 616 117 70 1.176 1.151 1.248 12 531 1.101 143 267 171
2023/20241.761 370 85 290 104 72 276 232 72 25 47 29 159
2024/202516.831 116 65 1.084 346 275 1.163 2.348 5.046 1.570 1.069 2.463 1.286
2025/202636.457 1.629 7.932 3.339 3.207 3.369 2.012 6.125 1.660 1.684 2.521 940 2.039
2026/20273.103 631 1.598 874 0 0 0 0 0 0 0 0 0
Totale 119.390